Clinical, magnetic resonance imaging, cerebrospinal fluid and electrophysiological characteristics of the earliest multiple sclerosis

被引:21
作者
Rot, Uros [1 ]
Ledinek, Alenka Horvat [1 ]
Jazbec, Sasa Sega [1 ]
机构
[1] Med Ctr, Dept Neurol, Ljubljana 1525, Slovenia
关键词
cerebrospinal fluid; clinical features; clinically isolated syndrome; evoked potentials; MRI; relapsing-remitting multiple sclerosis;
D O I
10.1016/j.clineuro.2007.11.001
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives: The vast majority of clinically isolated syndrome (CIS) patients with at least two silent brain MRI lesions progress to multiple sclerosis (MS) as early as after 2 years meaning that they actually have MS, the earliest MS. Effective therapy with interferon beta preparations in patients with the earliest MS demands early and accurate diagnosis of the disease. Patients and methods: In order to find the differentiating clinical and paraclinical characteristics of patients with the earliest MS we compared clinical, MRI, CSF and evoked potential findings in patients with the earliest MS and patients with relapsing-remitting (RR) MS. Retrospective analysis included 149 patients (103 women), among them 40 patients with the earliest MS and 95 patients with RR MS. Results: Patients with the earliest MS had more often predominant afferent symptoms (p = 0.023) but less often predominant cerebellar (p = 0.033) and efferent symptoms (p = 0.012) than patients with RR MS. They were less likely to fulfill the Barkhof brain MRI criteria (p = 0.050) and had less often prolonged latencies of visual evoked potentials (VEP) (p = 0.006) than patients with RR MS. On the other hand they were more likely to have elevated CSF cells (p = 0.010) than patients with RR MS and had as often present CSF oligoclonal bands (p = 0.112). Conclusion: The differentiating characteristics of patients with the earliest MS are predominance of afferent symptoms, less brain MRI dissemination and more frequently normal VEP, but on the other hand abnormal CSF findings with elevated CSF cells and positive oligoclonal bands. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:233 / 238
页数:6
相关论文
共 25 条
[1]  
BRECELJ J, 1994, MED RAZGL, V33, P339
[2]   SURVIVAL OF PATIENTS WITH MULTIPLE-SCLEROSIS IN DENMARK - A NATIONWIDE, LONG-TERM EPIDEMIOLOGIC SURVEY [J].
BRONNUMHANSEN, H ;
KOCHHENRIKSEN, N ;
HYLLESTED, K .
NEUROLOGY, 1994, 44 (10) :1901-1907
[3]   Effect of early interferon treatment on conversion to definite multiple sclerosis:: a randomised study [J].
Comi, G ;
Filippi, M ;
Barkhof, F ;
Durelli, L ;
Edan, G ;
Fernández, O ;
Hartung, HP ;
Seeldrayers, P ;
Sorensen, PS ;
Rovaris, M ;
Martinelli, V ;
Hommes, OR .
LANCET, 2001, 357 (9268) :1576-1582
[4]   Prospective study of patients presenting with acute partial transverse myelopathy [J].
Cordonnier, C ;
de Seze, J ;
Breteau, G ;
Ferriby, D ;
Michelin, E ;
Stojkovic, T ;
Pruvo, JP ;
Vermersch, P .
JOURNAL OF NEUROLOGY, 2003, 250 (12) :1447-1452
[5]   Spinal cord MRI in clinically isolated optic neuritis [J].
Dalton, CM ;
Brex, PA ;
Miszkiel, KA ;
Fernando, K ;
MacManus, DG ;
Plant, GT ;
Thompson, AJ ;
Miller, DH .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2003, 74 (11) :1577-1580
[6]   Application of the new McDonald criteria to patients with clinically isolated syndromes suggestive of multiple sclerosis [J].
Dalton, CM ;
Brex, PA ;
Miszkiel, KA ;
Hickman, SJ ;
MacManus, DG ;
Plant, GT ;
Thompson, AJ ;
Miller, DH .
ANNALS OF NEUROLOGY, 2002, 52 (01) :47-53
[7]  
DENISLIC M, 1987, ZDRAV VESTN, V56, P7
[8]   INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DUQUETTE, P ;
GIRARD, M ;
DESPAULT, L ;
DUBOIS, R ;
KNOBLER, RL ;
LUBLIN, FD ;
KELLEY, L ;
FRANCIS, GS ;
LAPIERRE, Y ;
ANTEL, J ;
FREEDMAN, M ;
HUM, S ;
GREENSTEIN, JI ;
MISHRA, B ;
MULDOON, J ;
WHITAKER, JN ;
EVANS, BK ;
LAYTON, B ;
SIBLEY, WA ;
LAGUNA, J ;
KRIKAWA, J ;
PATY, DW ;
OGER, JJ ;
KASTRUKOFF, LF ;
MOORE, GRW ;
HASHIMOTO, SA ;
MORRISON, W ;
NELSON, J ;
GOODIN, DS ;
MASSA, SM ;
GUTTERIDGE, E ;
ARNASON, BGW ;
NORONHA, A ;
REDER, AT ;
MARTIA, R ;
EBERS, GC ;
RICE, GPA ;
LESAUX, J ;
JOHNSON, KP ;
PANITCH, HS ;
BEVER, CT ;
CONWAY, K ;
WALLENBERG, JC ;
BEDELL, L ;
VANDENNOORT, S ;
WEINSHENKER, B ;
WEISS, W ;
REINGOLD, S ;
PACHNER, A ;
TAYLOR, W .
NEUROLOGY, 1993, 43 (04) :655-661
[9]   Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial [J].
Filippi, M ;
Rovaris, M ;
Inglese, M ;
Barkhof, F ;
De Stefano, N ;
Smith, S ;
Comi, G .
LANCET, 2004, 364 (9444) :1489-1496
[10]   Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. [J].
Jacobs, LD ;
Beck, RW ;
Simon, JH ;
Kinkel, RP ;
Brownscheidle, CM ;
Murray, TJ ;
Simonian, NA ;
Slasor, PJ ;
Sandrock, AW .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13) :898-904